MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

MC

459.25

-1.36%↓

SANES

9.484

-1.2%↓

SAF

283.6

-1.46%↓

BBVA

18.26

-0.79%↓

BNP

83.02

-0.41%↓

Search

IPSOS

Închisă

SectorFinanțe

33.74 -0.76

Rezumat

Modificarea prețului

24h

Curent

Minim

33.42

Maxim

34.56

Indicatori cheie

By Trading Economics

Venit

107M

133M

Vânzări

792M

1.4B

P/E

Medie Sector

8.91

54.048

Randament dividend

5.5

Marjă de profit

9.737

Angajați

20,000

EBITDA

194M

261M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+58.71% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

5.50%

4.84%

Statistici piață

By TradingEconomics

Capitalizare de piață

262M

1.6B

Deschiderea anterioară

34.5

Închiderea anterioară

33.74

Sentimentul știrilor

By Acuity

70%

30%

401 / 441 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

IPSOS Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 mar. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar. 2026, 22:55 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar. 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar. 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar. 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Global Equities Roundup: Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar. 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar. 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar. 2026, 22:18 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar. 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar. 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar. 2026, 21:10 UTC

Evenimente importante

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk
Câștiguri
Evenimente importante

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

IPSOS Așteptări

Obiectiv de preț

By TipRanks

58.71% sus

Prognoză pe 12 luni

Medie 53.23 EUR  58.71%

Maxim 72 EUR

Minim 36.7 EUR

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIPSOS - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

39.72 / 43Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

401 / 441 Clasament în Finanțe

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre IPSOS

Ipsos SA, through its subsidiaries, provides survey-based research services for companies and institutions in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company offers services in the information production and analysis chain, including data collection, data processing and integration, data analysis, information delivery and presentation, and information activation. It also provides audience measurement, automotive and mobility development, brand health tracking, channel performance, corporate reputation, creative excellence, customer experience, healthcare, innovation, Ipsos MMA, Ipsos UU, market strategy and understanding, observer, public affairs, social intelligence analytics, and other specialist services, as well as research methodologies, such as device agnosticism, programmatic sampling, and digital face-to-face interview. In addition, the company offers online and mobile integrated services and device agnostic solutions that include online surveys adapted to laptops, smartphones, and tablets; and qualitative research services, as well as operates Ipsos.Digital, a do-it-yourself platform. Further, it provides artificial intelligence and data science solutions that develops and provides analytical tools based on data science, machine learning, big analytics, and modelling; and behavioral science and neuroscience solutions, as well as operates Ipsos Knowledge Centre for teams and clients. Ipsos SA was incorporated in 1975 and is headquartered in Paris, France.
help-icon Live chat